Condition
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Locations
United States
Start date
02/10/2025
Identifiers
Trial ID NN6019-4958,
NCT number NCT07207811,
Eudract number Not Available
NCT number NCT07207811,
Eudract number Not Available
Summary
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Trial Overview:
Treatment
DRUG: NNC6019-0001
DRUG: Placebo (NNC6019-0001)
Study type
INTERVENTIONAL
Trial duration
Oct 02 2025 - Jun 29 2029
Participants
1280
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.